Last update 21 Nov 2024
Autologous Anti-CD19/CD20 CAR T-cell Therapy(Kite Pharma, Inc)
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), Immunologic cytotoxicity + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with Autologous Anti-CD19/CD20 CAR T-cell Therapy(Kite Pharma, Inc)Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
100 Clinical Results associated with Autologous Anti-CD19/CD20 CAR T-cell Therapy(Kite Pharma, Inc)
Login to view more data
100 Translational Medicine associated with Autologous Anti-CD19/CD20 CAR T-cell Therapy(Kite Pharma, Inc)
Login to view more data
100 Patents (Medical) associated with Autologous Anti-CD19/CD20 CAR T-cell Therapy(Kite Pharma, Inc)
Login to view more data
100 Deals associated with Autologous Anti-CD19/CD20 CAR T-cell Therapy(Kite Pharma, Inc)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hematologic Neoplasms | Phase 2 | US | 15 Dec 2021 | |
| Solid tumor | Phase 2 | US | 15 Dec 2021 | |
| Solid tumor | Phase 2 | NL | 15 Dec 2021 | |
| Solid tumor | Phase 2 | JP | 15 Dec 2021 | |
| Solid tumor | Phase 2 | DE | 15 Dec 2021 | |
| Solid tumor | Phase 2 | AU | 15 Dec 2021 | |
| Solid tumor | Phase 2 | FR | 15 Dec 2021 | |
| Solid tumor | Phase 2 | CA | 15 Dec 2021 | |
| Solid tumor | Phase 2 | GB | 15 Dec 2021 | |
| Solid tumor | Phase 2 | IL | 15 Dec 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free